Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2025International Journal of HematologyOpen Access

A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShigeru Kusumoto

Discussion

Loading...

Member takes

Overview

Phase 2 study shows 60% complete remission in untreated CLL, indicating a favorable safety and efficacy profile of venetoclax combined with ibrutinib.

Key Points

  • Complete remission rate reached 60%, exceeding the efficacy threshold of 10%.
  • The median treatment duration for venetoclax was 11 months in 10 patients with untreated CLL/SLL.
  • Multicenter, open-label study evaluated the combination treatment's safety and efficacy.
  • Results highlight a favorable benefit-risk profile with manageable adverse effects and high efficacy rates.

Cite This Study

Shigeru Kusumoto (2025) studied this question.

synapsesocial.com/papers/692e3d706c9b3ab28c186fa9https://doi.org/10.1007/s12185-025-04114-w
View Full Paper
Ask AI
Bookmark
Share